180002-02-2

Basic information

• Product Name: Carbamic acid, methyl[(3-nitrophenyl)methyl]-, 1,1-dimethylethyl ester
• CAS NO: 180002-02-2
• Molecular Formula: C13H18N2O4
• Molecular Weight: 266.297
• Mol File: 180002-02-2.mol
• Article Data: 5

Chemical Properties

• CAS DataBase Reference: Carbamic acid, methyl[(3-nitrophenyl)methyl]-, 1,1-dimethylethyl ester(CAS DataBase Reference)
• NIST Chemistry Reference: Carbamic acid, methyl[(3-nitrophenyl)methyl]-, 1,1-dimethylethyl ester(180002-02-2)
• EPA Substance Registry System: Carbamic acid, methyl[(3-nitrophenyl)methyl]-, 1,1-dimethylethyl ester(180002-02-2)

Safety Data

• Hazardous Substances Data: 180002-02-2(Hazardous Substances Data)

Upstream product

• 3958-57-4 1-bromomethyl-3-nitrobenzene 
• 24424-99-5 di-tert-butyl dicarbonate 
• 19499-61-7 methyl-(3-nitro-benzyl)-amine 
• 14666-77-4 di-t-butyl peroxydicarbonate 
• 26177-43-5 3-nitrobenzylamine hydrochloride 
• 147291-65-4 N-(3-nitrophenylmethyl)carbamic acid t-butyl ester 
• 74-88-4 methyl iodide 

Downstream Products

• 167756-90-3 tert-butyl N-[(3-aminophenyl)methyl]-N-methylcarbamate 

Relevant articles and documents

Installation of Pargyline, a LSD1 Inhibitor, in the HDAC Inhibitory Template Culminated in the Identification of a Tractable Antiprostate Cancer Agent

Pragmatic insertion of pargyline, a LSD1 inhibitor, as a surface recognition part in the HDAC inhibitory pharmacophore was planned in pursuit of furnishing potent antiprostate cancer agents. Resultantly, compound 14 elicited magnificent cell growth inhibi

MACROCYCLIC FACTOR VIIA INHIBITORS USEFUL AS ANTICOAGULANTS

The present invention relates generally to novel macrocycles of Formula (I) or stereoisomers, tautomers, pharmaceutically acceptable salts, solvates, or prodrugs thereof, wherein the variables A, B, C, D, L, M, W, Z1, Z2, Z3, Z4, R1, R2, R3, R4, R5, R6, R7, R8, R9, and R10 are as defined herein. These compounds are selective inhibitors of factor VIIa which can be used as medicaments.

N-phenylamidines as selective inhibitors of human neuronal nitric oxide synthase: Structure-activity studies and demonstration of in vivo activity

Selective inhibition of the neuronal isoform of nitric oxide synthase (NOS) compared to the endothelial and inducible isoforms may be required for treatment of neurological disorders caused by excessive production of nitric oxide. Recently, we described N-(3-(aminomethyl)benzyl)acetamidine (13) as a slow, tight-binding inhibitor, highly selective for human inducible nitric oxide synthase (iNOS). Removal of a single methylene bridge between the amidine nitrogen and phenyl ring to give N-(3- (aminomethyl)phenyl)acetamidine (14) dramatically altered the selectivity to give a neuronal selective nitric oxide synthase (nNOS) inhibitor. Part of this large shift in selectivity was due to 14 being a rapidly reversible inhibitor of iNOS in contrast to the essentially irreversible inhibition of iNOS observed with 13. Structure-activity studies revealed that a basic amine functionality tethered to an aromatic ring and a sterically compact amidine are key pharmacophores for this class of NOS inhibitors. Maximal nNOS inhibition potency was achieved with N-(3-(aminomethyl)phenyl)-2- furanylamidine (77) (K(i-nNOS) = 0.006 μM; K(i-eNOS) = 0.35 μM; K(i-iNOS) = 0.16 μM). Finally, α-fluoro-N-(3-(aminomethyl)phenyl)acetamidine (74) (K(i- nNOS) = 0.011 μM; K(i-eNOS) = 1.1 μM; K(i-iNOS) = 0.48 μM) had excellent brain penetration and inhibited nNOS in a rat brain slice assay as well as in the rat brain (cerebellum) in vivo. Thus, N-phenylamidines should be useful in validating the role of nNOS in neurological disorders.